Ageing with HIV: a Multidisciplinary Review

Overview

Journal Infection

Date 2015 May 20

PMID 25987480

Citations 13

Authors

A Calcagno

S Nozza

C Muss

B M Celesia

F Carli

S Piconi

G V De Socio

A M Cattelan

G Orofino

D Ripamonti

A Riva

G Di Perri

Affiliations

Soon will be listed here.

Abstract

Introduction: After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old.

Material And Methods: This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients.

Conclusion And Discussion: We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.

Citing Articles

The Intersection of HIV and Pulmonary Vascular Health: From HIV Evolution to Vascular Cell Types to Disease Mechanisms.

Garcia A, Almodovar S J Vasc Dis. 2024; 3(2):174-200.

PMID: 39464800 PMC: 11507615. DOI: 10.3390/jvd3020015.

DNA methylation-based telomere length is associated with HIV infection, physical frailty, cancer, and all-cause mortality.

Liang X, Aouizerat B, So-Armah K, Cohen M, Marconi V, Xu K Aging Cell. 2024; 23(7):e14174.

PMID: 38629454 PMC: 11258465. DOI: 10.1111/acel.14174.

Epidemiological characteristics and adherence of a cohort of elderly people with HIV/AIDS in the Public Health System.

Ferreira C, Leite I Einstein (Sao Paulo). 2022; 20:eAO6474.

PMID: 35352767 PMC: 8932733. DOI: 10.31744/einstein_journal/2022AO6474.

Aging with HIV: Increased Risk of HIV Comorbidities in Older Adults.

Roomaney R, van Wyk B, Pillay-van Wyk V Int J Environ Res Public Health. 2022; 19(4).

PMID: 35206544 PMC: 8872228. DOI: 10.3390/ijerph19042359.

Expression of Killer Immunoglobulin Receptor Genes among HIV-Infected Individuals with Non-AIDS Comorbidities.

Abou Hassan F, Bou Hamdan M, El Asmar K, Melhem N J Immunol Res. 2022; 2022:1119611.

PMID: 35071606 PMC: 8769865. DOI: 10.1155/2022/1119611.

References

Pettersen F, Torheim E, Dahm A, Aaberge I, Lind A, Holm M . An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol. 2011; 85(13):6557-66. PMC: 3126508. DOI: 10.1128/JVI.00073-11. View

Justice A, Dombrowski E, Conigliaro J, Fultz S, Gibson D, Madenwald T . Veterans Aging Cohort Study (VACS): Overview and description. Med Care. 2006; 44(8 Suppl 2):S13-24. PMC: 3049942. DOI: 10.1097/01.mlr.0000223741.02074.66. View

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E . Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011; 6(7):e22661. PMC: 3143186. DOI: 10.1371/journal.pone.0022661. View

Bedimo R, Westfall A, Drechsler H, Vidiella G, Tebas P . Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011; 53(1):84-91. DOI: 10.1093/cid/cir269. View

Eckard A, McComsey G . Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals. Curr HIV/AIDS Rep. 2014; 11(3):263-70. PMC: 4125449. DOI: 10.1007/s11904-014-0218-8. View

Shepherd L, Souberbielle J, Bastard J, Fellahi S, Capeau J, Reekie J . Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis. 2014; 210(2):234-43. DOI: 10.1093/infdis/jiu074. View

Kitamura A, Tsurugizawa T, Uematsu A, Torii K, Uneyama H . New therapeutic strategy for amino acid medicine: effects of dietary glutamate on gut and brain function. J Pharmacol Sci. 2012; 118(2):138-44. DOI: 10.1254/jphs.11r06fm. View

Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S . Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2012; 62(4):375-80. DOI: 10.1097/QAI.0b013e31827ce4ee. View

Calcagno A, Alberione M, Romito A, Imperiale D, Ghisetti V, Audagnotto S . Prevalence and predictors of blood-brain barrier damage in the HAART era. J Neurovirol. 2014; 20(5):521-5. DOI: 10.1007/s13365-014-0266-2. View

10.

Alcaide M, Parmigiani A, Pallikkuth S, Roach M, Freguja R, Della Negra M . Immune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study. PLoS One. 2013; 8(5):e63804. PMC: 3665816. DOI: 10.1371/journal.pone.0063804. View

11.

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

12.

Freiberg M, Chang C, Kuller L, Skanderson M, Lowy E, Kraemer K . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8):614-22. PMC: 4766798. DOI: 10.1001/jamainternmed.2013.3728. View

13.

Gualano B, Roschel H, Lancha Jr A, Brightbill C, Rawson E . In sickness and in health: the widespread application of creatine supplementation. Amino Acids. 2011; 43(2):519-29. DOI: 10.1007/s00726-011-1132-7. View

14.

Klatt N, Canary L, Sun X, Vinton C, Funderburg N, Morcock D . Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013; 123(2):903-7. PMC: 3561826. DOI: 10.1172/JCI66227. View

15.

Funderburg N, Jiang Y, Debanne S, Storer N, Labbato D, Clagett B . Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2013; 58(4):588-95. PMC: 3905756. DOI: 10.1093/cid/cit748. View

16.

Detels R, Jacobson L, Margolick J, Martinez-Maza O, Munoz A, Phair J . The multicenter AIDS Cohort Study, 1983 to …. Public Health. 2011; 126(3):196-198. PMC: 3324261. DOI: 10.1016/j.puhe.2011.11.013. View

17.

Gonzalez-Hernandez L, Jave-Suarez L, Fafutis-Morris M, Montes-Salcedo K, Valle-Gutierrez L, Campos-Loza A . Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. Nutr J. 2012; 11:90. PMC: 3494555. DOI: 10.1186/1475-2891-11-90. View

18.

Brothers T, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston B . Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis. 2014; 210(8):1170-9. DOI: 10.1093/infdis/jiu258. View

19.

Ripps H, Shen W . Review: taurine: a "very essential" amino acid. Mol Vis. 2012; 18:2673-86. PMC: 3501277. View

20.

Zanni M, Fitch K, Feldpausch M, Han A, Lee H, Lu M . 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014; 28(14):2061-70. PMC: 4405159. DOI: 10.1097/QAD.0000000000000360. View